Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and HUTCHMED (China) Limited's Expenses

Comparative cost analysis of Regeneron and HUTCHMED from 2014-2023.

__timestampHUTCHMED (China) LimitedRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201472049000205018000
Thursday, January 1, 2015110777000392709000
Friday, January 1, 2016156328000299694000
Sunday, January 1, 2017175820000397061000
Monday, January 1, 2018143944000434100000
Tuesday, January 1, 2019160152000782200000
Wednesday, January 1, 20201885190001119900000
Friday, January 1, 20212582340002437500000
Saturday, January 1, 20223111030001560400000
Sunday, January 1, 20233844470001815800000
Monday, January 1, 20241970500000
Loading chart...

In pursuit of knowledge

Cost Insights: A Comparative Analysis of Regeneron Pharmaceuticals and HUTCHMED (China) Limited

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Regeneron Pharmaceuticals, Inc. and HUTCHMED (China) Limited from 2014 to 2023. Over this period, Regeneron has consistently outpaced HUTCHMED, with its cost of revenue peaking at approximately $1.82 billion in 2023, a staggering 780% increase from 2014. In contrast, HUTCHMED's cost of revenue grew by 434% over the same period, reaching around $384 million in 2023. This disparity highlights Regeneron's expansive growth and market dominance. However, HUTCHMED's steady increase reflects its strategic positioning in the competitive Chinese market. As the pharmaceutical landscape continues to shift, these insights provide a window into the financial strategies of two key players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025